Related Experiment Video
Updated: Nov 21, 2025

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
Unsupervised hierarchical clustering identifies a metabolically challenged subgroup of hypertensive individuals
Felix C Vaura1, Veikko V Salomaa2, Ilkka M Kantola3
1Department of Medicine, University of Turku, Turku, Finland.
Insights
This study identified two distinct hypertension phenotypes using cluster analysis. One group, the Metabolically Challenged, showed significantly higher cardiovascular disease risk, suggesting a need for personalized hypertension management.
Area of Science:
- Cardiology
- Metabolic Syndrome
- Hypertension Research
Background:
- Current hypertension classification lacks granularity regarding patient heterogeneity and cardiovascular outcomes.
- Identifying distinct hypertension phenotypes is crucial for understanding differential cardiovascular risk.
Purpose of the Study:
- To identify distinct hypertension phenotypes using data-driven cluster analysis.
- To assess the cardiovascular disease (CVD) risk profiles associated with these identified phenotypes.
Main Methods:
- Cluster analysis was performed on 3726 individuals with grade 2 hypertension from FINRISK cohorts.
- Eight factors including blood pressure, cholesterol, glucose, BMI, CRP, eGFR, and alcohol intake were used for clustering.
- Cox regression models assessed CVD outcomes relative to identified clusters and a reference group.
Main Results:
- Two comparable hypertension clusters were identified in both men and women.
- The Metabolically Challenged (MC) cluster exhibited elevated blood glucose and BMI.
- The MC cluster demonstrated a 1.6-fold increased CVD risk compared to non-MC individuals and a 2.5-fold risk compared to the reference group.
Conclusions:
- Unsupervised hierarchical clustering revealed two distinct hypertension subgroups with varying CVD risks.
- This phenotypic substratification can inform studies on differential antihypertensive therapy effects in hypertension subgroups.
Abstract:
The current classification of hypertension does not reflect the heterogeneity in characteristics or cardiovascular outcomes of hypertensive individuals. Our objective was to identify distinct phenotypes of hypertensive individuals with potentially different cardiovascular risk profiles using data-driven cluster analysis. We performed clustering, a procedure that identifies groups with similar characteristics, in 3726 individuals (mean age 59.4 years, 49% women) with grade 2 hypertension (blood pressure ≥160/100 mmHg or antihypertensive medication) selected from FINRISK 1997, 2002, and 2007 cohorts. We computed clusters based on eight factors associated with hypertension: mean arterial pressure, pulse pressure, non-high-density lipoprotein cholesterol, blood glucose, BMI, C-reactive protein, estimated glomerular filtration rate, and alcohol. After that, we used Cox regression models adjusted for age and sex to assess the relative risk of cardiovascular disease (CVD) outcomes between the clusters and a reference group of 11 020 individuals. We observed two comparable clusters in both men and women. The Metabolically Challenged (MC) cluster was characterized by high blood glucose (Z-score 4.4 ± 1.1 vs 0.2 ± 0.8, men; 3.5 ± 1.1 vs 0.0 ± 0.6, women) and elevated BMI (30.4 ± 4.1 vs 28.9 ± 4.3, men; 32.7 ± 4.9 vs 29.3 ± 5.5, women). Over a 10-year follow-up (1034 CVD events), MC had 1.6-fold (95% CI 1.1-2.4) CVD risk compared to non-MC and 2.5-fold (95% CI 1.7-3.7) CVD risk compared to the reference group (P ≤ .009 for both). Using unsupervised hierarchical clustering, we found two phenotypically distinct hypertension subgroups with different risks of CVD complications. This substratification could be used to design studies that explore the differential effects of antihypertensive therapies among subgroups of hypertensive individuals.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension II: Pathophysiology

